Bukhari Sumera, Ward Kristine, Styler Michael
Cambridge Health Alliance-Harvard Medical School, Boston, Massachusetts, USA.
Pennsylvania Hospital-Penn Medicine, Philadelphia, Pennsylvania, USA.
Case Rep Oncol Med. 2020 Dec 1;2020:8254236. doi: 10.1155/2020/8254236. eCollection 2020.
Hepatocellular carcinoma (HCC) most commonly presents with abdominal pain or mass, fever of unknown etiology, weight loss, and decompensation of known liver disease or at an asymptomatic stage through surveillance. Rarely, presenting symptoms can be exclusively related to extrahepatic metastases. Herein, we write a case of a patient with no known liver disease, presenting with a pathological fracture of the proximal humerus bone secondary to a massive solitary metastasis from HCC. This case represents an unusual appendicular skeletal metastasis in a patient with unknown primary HCC, successfully treated with sorafenib. The prognosis of HCC patients with extrahepatic metastasis is poor, and in the presence of bone metastases, the mean survival rate is severely reduced. However, the multikinase inhibitor sorafenib has been the standard of treatment. Recently, there has been developments of other therapeutic class of drugs (i.e., immune check inhibitors), which have shown promising benefits and better side effect profiles. Still, there is a need for further studies, owing to challenges in recognizing cellular and molecular markers.
肝细胞癌(HCC)最常见的表现为腹痛或肿块、不明原因发热、体重减轻,以及已知肝病失代偿或通过监测处于无症状阶段。很少见的情况是,出现的症状可能仅与肝外转移有关。在此,我们报告一例无已知肝病的患者,因HCC巨大孤立转移导致肱骨近端病理性骨折。该病例代表了一例原发性HCC不明的患者出现的不寻常的四肢骨骼转移,经索拉非尼成功治疗。HCC肝外转移患者的预后较差,存在骨转移时,平均生存率会严重降低。然而,多激酶抑制剂索拉非尼一直是治疗的标准药物。最近,其他治疗类别的药物(即免疫检查抑制剂)有了新进展,已显示出有前景的疗效和更好的副作用特征。不过,由于在识别细胞和分子标志物方面存在挑战,仍需要进一步研究。